Bernard Munos, one of the sharpest critics of the drug development industry, takes Big Pharma to task once again on the innovation front after reviewing just what's been approved over the past 12 years.
A Japanese biotech named Prism Pharma says it has raised $15 million to back clinical trials for a lead cancer therapy now under way at MD Anderson in Houston.
Swiss researchers may have discovered a master switch for cancer metastasis, a process that forms secondary tumors and is the leading cause of death among cancer patients.
CHICAGO --The showdown between Bristol-Myers Squibb ($BMY) and Merck ($MRK) over a new PD-1 approach to spurring an immune response to cancer didn't disappoint.
Just a year or two ago, analysts and investors were in a frenzy over the frantic race to develop a new set of hepatitis C drugs that promised to change the standard of care. Now, as the leaders in that race approach the first round of likely marketing approvals, a new R&D competition has grabbed analysts' feverish attention as the next big thing in biopharma. And the leading players in this field may once again be betting on a mega-blockbuster payoff.
MIT researchers may have discovered a key protein involved in cell death--one that could help kill remaining cancer cells after chemotherapy.
Bristol-Myers Squibb has emerged, at least temporarily, as the leader in a race to develop the first new PD-1 drug to fight cancer.
Determined to prove to investors that AstraZeneca has a late-stage game plan that can rescue the pharma company from a lengthy losing streak, the company today spotlighted plans to speed up the Phase III development timeline on three key cancer drugs.
The economist Edward Fiedler famously said "He who lives by the crystal ball soon learns to eat ground glass," a statement to whose veracity I can readily attest having written widely on the potential of genomics during my tenure on Wall Street. Read the feature >>
Symphogen has replenished its coffers with 41 million euros ($53.7 million) as the Danish biotech makes progress with next-generation antibody drugs for treating cancer. The latest capital infusion adds to 100 million euros ($130.9 million) that the company previously raised in 2011 for the round, giving the company about 100 million euros in cash as of today, according to the group's press release.